Topic

Chris Spivey is the editorial director of 

Articles

Andy Geall, co-founder and chief development officer at Replicate Bioscience continues the discussion on the development history of mRNA therapeutics.

Discussing the Origins of the mRNA Therapeutics Field (Part Two)

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Autifony Signs $770.5 Million License and Collaboration with Jazz Pharmaceuticals

A look into the latest developments in biopharmaceutical manufacturing and facilities.


Update on Facilities and Manufacturing Trends

Feliza Mirasol is the science editor for 

Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.

Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies

A discussion with Thomas Langenickel, MD, chief medical officer at Ethris, shines a light on how advances made with mRNA technology are also advancing the industry’s ability to focus on treatment of rare diseases, such as rare lung diseases.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part One)

Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation highlights how current technologies are enabling oligonucleotide development.

Oligonucleotide-Enabling Technology Pushes Oligos to the Forefront (AAPS PharmSci 360)

Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation, considers that status of oligonucleotides on the market.

Oligonucleotides: The Next Therapeutic Wave on the Market? (AAPS PharmSci 360)

Editor of Pharmaceutical Technology Europe

Innovative strategies and good partnerships are means by which developers can overcome the unique challenges in biologics formulation. 

Learning How to Navigate Biologics Development

Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.

Discussing Oligonucleotide Challenges in Analytics and Purification (AAPS PharmSci 360)

As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.

BioBusiness